Do Social Media and Blogs Have a Positive Impact on Patient Quality of Life?

Article

Last week, well-known Canadian blogger Derek Miller's final blog entry was posted on his site, penmachine.com. Miller, who died on May 3 at the age of 41, was diagnosed with stage IV metastatic colorectal cancer in 2007.

Last week, well-known Canadian blogger Derek Miller's final blog entry was posted on his site, penmachine.com. Miller, who died on May 3 at the age of 41, was diagnosed with stage IV metastatic colorectal cancer in 2007.

"Here it is. I'm dead, and this is my last post to my blog. In advance, I asked that once my body finally shut down from the punishments of my cancer, then my family and friends publish this prepared message I wrote the first part of the process of turning this from an active website to an archive," read the post.

In this era of social media and blogging, online interaction often surpasses time spent with friends and family in person. For many, it has also created an outlet for expression that perhaps didn't exist for them before.

 

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Related Content